Author
Apar Kishor Ganti
Other affiliations: United States Department of Veterans Affairs, University of North Dakota, Nebraska Medical Center ...read more
Bio: Apar Kishor Ganti is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 39, co-authored 241 publications receiving 6378 citations. Previous affiliations of Apar Kishor Ganti include United States Department of Veterans Affairs & University of North Dakota.
Topics: Lung cancer, Cancer, Medicine, Internal medicine, Hazard ratio
Papers published on a yearly basis
Papers
More filters
University of California, San Diego1, Université de Montréal2, French Institute of Health and Medical Research3, Versailles Saint-Quentin-en-Yvelines University4, Curie Institute5, Instituto Português de Oncologia Francisco Gentil6, University of Milan7, Samsung8, Université catholique de Louvain9, Cliniques Universitaires Saint-Luc10, Fox Chase Cancer Center11, Yale University12, Merck & Co.13, The Royal Marsden NHS Foundation Trust14, Institute of Cancer Research15
TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.
984 citations
TL;DR: A further understanding of the system is required to develop an effective anticancer regimen and a combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific molecular oriented remedy.
Abstract: Introduction: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation. Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts. Areas covered: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression. Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also pre...
704 citations
Johns Hopkins University1, University of Utah2, University of South Florida3, Fox Chase Cancer Center4, Roswell Park Cancer Institute5, Brigham and Women's Hospital6, Duke University7, City of Hope National Medical Center8, University of California, San Francisco9, University Of Tennessee System10, University of Michigan11, Memorial Sloan Kettering Cancer Center12, Stanford University13, Harvard University14, University of Alabama at Birmingham15, Ohio State University16, Houston Methodist Hospital17, Seattle Cancer Care Alliance18
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (SCLC) focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease as discussed by the authors.
Abstract: Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.
514 citations
Johns Hopkins University1, University of Utah2, Fox Chase Cancer Center3, University of Michigan4, Roswell Park Cancer Institute5, Brigham and Women's Hospital6, Duke University7, Washington University in St. Louis8, City of Hope National Medical Center9, Vanderbilt University10, University of California, San Francisco11, University Of Tennessee System12, University of Nebraska–Lincoln13, University of Texas MD Anderson Cancer Center14, Memorial Sloan Kettering Cancer Center15, Harvard University16, Stanford University17, Seattle Cancer Care Alliance18, University of Alabama19, Ohio State University20, Northwestern University21, University of South Florida22
TL;DR: These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on malignant pleural mesothelioma (MPM), which is the most common type.
Abstract: malignant pleural mesothelioma is a relatively uncommon disease associated with asbestos exposure. its incidence increased markedly following the widespread mining and use of asbestos in many industries. the legal aspects regarding compensation cases for those who have developed this disease has raised its profile in the media, but also compounds the stress of diagnosis for patients. it has an insidious onset and may clinically and pathologically mimic other benign or malignant processes, complicating diagnosis. radical surgery may be used for a highly selected population of malignant pleural mesothelioma patients in the context of multimodality treatment in an experienced thoracic surgical centre, but there is no randomised evidence to support its benefit. in most cases surgery is used to treat symptoms or obtain tissue for diagnosis. Combination of a platinum agent and pemetrexed is now widely used and shown to prolong life. other treatments including radiotherapy, analgesics and supportive interventions are an integral part of the treatment of this disease. Further research is being undertaken on promising novel therapies for use in this disease, which will be discussed in this review. malignant pleural mesothelioma (mpm) is a neoplasm originating from mesothelial cells, which form the membranes surrounding the lung cavities. it is currently a disease mainly of the industrialised world, closely linked to asbestos exposure.1 seldom diagnosed prior to the advent of widespread asbestos mining in the early to mid twentieth century, it has risen in incidence over the last five decades.2, 3 according to the most recent australian institute of health and Welfare data, in 2009 there were 666 cases of malignant mesothelioma diagnosed in australia.4 this review will provide a brief overview of the diagnosis, current treatment modalities and some novel systemic treatment strategies that have been explored in mpm. Asbestos and malignant mesothelioma mpm is a disease with particular relevance to australia. Asbestos was first mined in Australia in the 1880s near Jones Creek, a town in nsW.5 it was not until the late 1940s when the insulating properties of asbestos rendered it a useful product in the building industry during the post war building boom, and subsequent demand for asbestos saw mining production rise exponentially in mines in nsW, tasmania, south australia and Western australia.5 there has also been widespread exposure within the building and transport industries in which asbestos was broadly utilised.6 Asbestos mining ended in Australia in 1983, and it is expected that malignant mesothelioma related to occupational exposure will plateau in the coming decade. in a Western Australian study, however, a significant increase was noted in the number of people being diagnosed with malignant meosthelioma whose only exposure to asbestos must have occurred in a non-occupational setting (most likely during home maintenance and renovation). Between 2005 and 2008, 8% of males and 5% of females diagnosed with malignant mesothelioma in this series reported non-occupational exposure as their only exposure to asbestos.6 these observations ask for confirmation in a case-controlled epidemiological study.
393 citations
University of Michigan1, Stanford University2, University of Utah3, Vanderbilt University4, University of Wisconsin-Madison5, Fox Chase Cancer Center6, Yale Cancer Center7, University of Alabama at Birmingham8, Case Western Reserve University9, Memorial Sloan Kettering Cancer Center10, University of Nebraska Medical Center11, Ohio State University12, University of California, San Francisco13, Johns Hopkins University14, Harvard University15, City of Hope National Medical Center16, Northwestern University17, Mayo Clinic18, University of Texas MD Anderson Cancer Center19, Washington University in St. Louis20, Roswell Park Cancer Institute21, University of Tennessee Health Science Center22, University of Colorado Boulder23, Fred Hutchinson Cancer Research Center24, University of South Florida25, National Comprehensive Cancer Network26
TL;DR: The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management regarding immunotherapy, systemic therapy, and radiation therapy and new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review."
Abstract: The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review."
197 citations
Cited by
More filters
TL;DR: In the United States, the cancer death rate has dropped continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment as mentioned in this paper.
Abstract: Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.
9,661 citations
TL;DR: The 11th edition of Harrison's Principles of Internal Medicine welcomes Anthony Fauci to its editorial staff, in addition to more than 85 new contributors.
Abstract: The 11th edition of Harrison's Principles of Internal Medicine welcomes Anthony Fauci to its editorial staff, in addition to more than 85 new contributors. While the organization of the book is similar to previous editions, major emphasis has been placed on disorders that affect multiple organ systems. Important advances in genetics, immunology, and oncology are emphasized. Many chapters of the book have been rewritten and describe major advances in internal medicine. Subjects that received only a paragraph or two of attention in previous editions are now covered in entire chapters. Among the chapters that have been extensively revised are the chapters on infections in the compromised host, on skin rashes in infections, on many of the viral infections, including cytomegalovirus and Epstein-Barr virus, on sexually transmitted diseases, on diabetes mellitus, on disorders of bone and mineral metabolism, and on lymphadenopathy and splenomegaly. The major revisions in these chapters and many
6,968 citations
[...]
01 Feb 2009
TL;DR: This Secret History documentary follows experts as they pick through the evidence and reveal why the plague killed on such a scale, and what might be coming next.
Abstract: Secret History: Return of the Black Death Channel 4, 7-8pm In 1348 the Black Death swept through London, killing people within days of the appearance of their first symptoms. Exactly how many died, and why, has long been a mystery. This Secret History documentary follows experts as they pick through the evidence and reveal why the plague killed on such a scale. And they ask, what might be coming next?
5,234 citations
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Abstract: BackgroundOsimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation–positive advanced non–small-cell lung cancer (NSCLC). MethodsIn this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation–positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-assessed progression-free survival. ResultsThe median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confi...
3,074 citations
Journal Article•
2,777 citations